Replimune Group, Inc. (REPL) — 10-Q Filings
All 10-Q filings from Replimune Group, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Replimune's Losses Widen Amid Soaring R&D, SG&A Costs
— Nov 6, 2025 Risk: high
Replimune Group, Inc. reported a significant increase in net loss for the three and six months ended September 30, 2025, primarily driven by higher operating ex -
Replimune Continues R&D Spend, No Revenue in Q1 2026
— Aug 7, 2025 Risk: high
Replimune Group, Inc. reported no revenue for the quarter ended June 30, 2025, consistent with the prior year, as it remains a clinical-stage biotechnology comp -
Replimune Group Files Q3 2024 10-Q
— Feb 12, 2025 Risk: medium
Replimune Group, Inc. filed its 10-Q for the period ending December 31, 2024. The company, based in Woburn, MA, operates in the biological products sector. This -
Replimune Reports Q2 Loss, R&D Expenses Rise
— Nov 12, 2024 Risk: medium
Replimune Group, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported a net loss of $101.7 million for the three months ended Sept -
Replimune Group Files Q1 FY25 10-Q
— Aug 8, 2024 Risk: medium
Replimune Group, Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance and business operations. The company, based in -
Replimune Group, Inc. Files 10-Q for Period Ending December 31, 2023
— Feb 8, 2024 Risk: low
Replimune Group, Inc. (REPL) filed a Quarterly Report (10-Q) with the SEC on February 8, 2024. Replimune Group, Inc. filed a 10-Q report for the period ending D
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX